Download PDF
CC BY 4.0 · TH Open 2023; 07(01): e65-e75
DOI: 10.1055/a-2009-9073
Original Article

Sepsis-Associated DIC with Decreased Levels of Antithrombin and Fibrinogen is the Target for Combination Therapy with Thrombomodulin Alfa and Antithrombin

Hideo Wada
1   Department of General Medicine, Mie Prefectural General Medical Center, Mie, Japan
,
Kazuo Kawasugi
2   Faculty of Medical Technology, Teikyo University, Tokyo, Japan
,
Goichi Honda
3   Department of Medical Affairs, Asahi Kasei Pharma Corporation, Tokyo, Japan
,
Noriaki Kawano
4   Department of Internal Medicine, Miyazaki Prefectural Miyazaki Hospital, Miyazaki, Japan
,
Toshimasa Uchiyama
5   Department of Laboratory Medicine, National Hospital Organization Takasaki General Medical Center, Gunma, Japan
,
Seiji Madoiwa
6   Department of Clinical Laboratory Medicine, Tokyo Saiseikai Central Hospital, Tokyo, Japan
,
Naoki Takezako
7   Department of Hematology, Nerima Hikarigaoka Hospital, Tokyo, Japan
,
Kei Suzuki
8   Emergency and Critical Care Center, Mie University Hospital, Mie, Japan
,
Yoshinobu Seki
9   Department of Hematology, Uonuma Institute of Community Medicine, Niigata University Medical and Dental Hospital, Niigata, Japan
,
Takayuki Ikezoe
10   Department of Hematology, Fukushima Medical University, Fukushima, Japan
,
Toshiaki Iba
11   Department of Emergency and Disaster Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan
,
Kohji Okamoto
12   Department of Surgery, Center for Gastroenterology and Liver Disease, Kitakyushu City Yahata Hospital, Fukuoka, Japan
› Author Affiliations Funding This work was supported by Asahi Kasei Pharma Corporation, which funded the analysis and English editing of the manuscript.
› Further Information
   Permissions and Reprints


Abstract

Background Disseminated intravascular coagulation (DIC) is not a homogeneous condition, but rather includes heterogeneous conditions, and its pathophysiology and outcome vary considerably depending on the background. Although anticoagulant therapy is expected to be of benefit in the treatment of DIC, previous studies have suggested that the benefits are limited only to a specific subtype.

Objects The purpose of this study was to identify the group that would benefit from combination therapy using thrombomodulin/antithrombin.

Methods The data from 2,839 patients registered in the postmarketing surveillance of thrombomodulin were evaluated. The patients were divided into four groups depending on antithrombin and fibrinogen levels, and the additive effects of antithrombin on thrombomodulin were examined in the groups.

Results The DIC score, Sequential Organ Failure Assessment score, and mortality were significantly higher in the DIC group with low-antithrombin/low-fibrinogen than in the DIC groups without either low antithrombin or low fibrinogen. The survival curve was significantly higher in DIC patients with combination therapy than in patients treated with thrombomodulin monotherapy, but this effect was seen only in patients with infection-based DIC.

Conclusion DIC patients with low-antithrombin/low-fibrinogen risk poor outcomes, but they can be the target of combination therapy with antithrombin and thrombomodulin as long as the DIC is due to infection.

Keywords

thrombomodulin - antithrombin - fibrinogen - disseminated intravascular coagulation - sepsis

Data Availability Statement

The data that support the findings of this study are available from Asahi Kasei Pharma Corporation, but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available.




Publication History

Received: 28 September 2022

Accepted: 03 January 2023

Accepted Manuscript online:
10 January 2023

Article published online:
22 February 2023

© 2023. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Adelborg K, Larsen JB, Hvas AM. Disseminated intravascular coagulation: epidemiology, biomarkers, and management. Br J Haematol 2021; 192 (05) 803-818
    CrossrefPubMedGoogle Scholar
  • 2 Gando S, Levi M, Toh CH. Disseminated intravascular coagulation. Nat Rev Dis Primers 2016; 2: 16037
    CrossrefPubMedGoogle Scholar
  • 3 Wada H, Matsumoto T, Yamashita Y, Hatada T. Disseminated intravascular coagulation: testing and diagnosis. Clin Chim Acta 2014; 436: 130-134
    CrossrefPubMedGoogle Scholar
  • 4 Taylor Jr FB, Toh CH, Hoots WK, Wada H, Levi M. Scientific Subcommittee on Disseminated Intravascular Coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH). Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost 2001; 86 (05) 1327-1330
    Article in Thieme ConnectPubMedGoogle Scholar
  • 5 Wada H, Matsumoto T, Yamashita Y. Diagnosis and treatment of disseminated intravascular coagulation (DIC) according to four DIC guidelines. J Intensive Care 2014; 2 (01) 15
    CrossrefPubMedGoogle Scholar
  • 6 Wada H, Matsumoto T, Hatada T. Diagnostic criteria and laboratory tests for disseminated intravascular coagulation. Expert Rev Hematol 2012; 5 (06) 643-652
    CrossrefPubMedGoogle Scholar
  • 7 Gando S, Iba T, Eguchi Y. et al; Japanese Association for Acute Medicine Disseminated Intravascular Coagulation (JAAM DIC) Study Group. A multicenter, prospective validation of disseminated intravascular coagulation diagnostic criteria for critically ill patients: comparing current criteria. Crit Care Med 2006; 34 (03) 625-631
    CrossrefPubMedGoogle Scholar
  • 8 Asakura H, Takahashi H, Uchiyama T. et al; DIC subcommittee of the Japanese Society on Thrombosis and Hemostasis. Proposal for new diagnostic criteria for DIC from the Japanese Society on Thrombosis and Hemostasis. Thromb J 2016; 14: 42
    CrossrefPubMedGoogle Scholar
  • 9 Wada H, Takahashi H, Uchiyama T. et al; DIC subcommittee of the Japanese Society on Thrombosis and Hemostasis. The approval of revised diagnostic criteria for DIC from the Japanese Society on Thrombosis and Hemostasis. Thromb J 2017; 15: 17
    CrossrefPubMedGoogle Scholar
  • 10 Levi M, Toh CH, Thachil J, Watson HG. British Committee for Standards in Haematology. Guidelines for the diagnosis and management of disseminated intravascular coagulation. Br J Haematol 2009; 145 (01) 24-33
    CrossrefPubMedGoogle Scholar
  • 11 Wada H, Asakura H, Okamoto K. et al; Japanese Society of Thrombosis Hemostasis/DIC subcommittee. Expert consensus for the treatment of disseminated intravascular coagulation in Japan. Thromb Res 2010; 125 (01) 6-11
    CrossrefPubMedGoogle Scholar
  • 12 Di Nisio M, Baudo F, Cosmi B. et al; Italian Society for Thrombosis and Haemostasis. Diagnosis and treatment of disseminated intravascular coagulation: guidelines of the Italian Society for Haemostasis and Thrombosis (SISET). Thromb Res 2012; 129 (05) e177-e184
    CrossrefPubMedGoogle Scholar
  • 13 Wada H, Thachil J, Di Nisio M. et al; The Scientific Standardization Committee on DIC of the International Society on Thrombosis Haemostasis. Guidance for diagnosis and treatment of DIC from harmonization of the recommendations from three guidelines. J Thromb Haemost 2013; 11 (04) 761-767
    CrossrefPubMedGoogle Scholar
  • 14 Wada H, Okamoto K, Iba T. et al; Japanese Society of Thrombosis Hemostasis/DIC subcommittee. Addition of recommendations for the use of recombinant human thrombomodulin to the “Expert consensus for the treatment of disseminated intravascular coagulation in Japan”. Thromb Res 2014; 134 (04) 924-925
    CrossrefPubMedGoogle Scholar
  • 15 Saito H, Maruyama I, Shimazaki S. et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost 2007; 5 (01) 31-41
    CrossrefPubMedGoogle Scholar
  • 16 Mimuro J, Takahashi H, Kitajima I. et al. Impact of recombinant soluble thrombomodulin (thrombomodulin alfa) on disseminated intravascular coagulation. Thromb Res 2013; 131 (05) 436-443
    CrossrefPubMedGoogle Scholar
  • 17 Asakura H, Takahashi H, Tsuji H. et al. Post-marketing surveillance of thrombomodulin alfa, a novel treatment of disseminated intravascular coagulation - safety and efficacy in 1,032 patients with hematologic malignancy. Thromb Res 2014; 133 (03) 364-370
    CrossrefPubMedGoogle Scholar
  • 18 Eguchi Y, Gando S, Ishikura H. et al. Post-marketing surveillance data of thrombomodulin alfa: sub-analysis in patients with sepsis-induced disseminated intravascular coagulation. J Intensive Care 2014; 2 (01) 30
    CrossrefPubMedGoogle Scholar
  • 19 Warren BL, Eid A, Singer P. et al; KyberSept Trial Study Group. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 2001; 286 (15) 1869-1878
    CrossrefPubMedGoogle Scholar
  • 20 Ranieri VM, Thompson BT, Barie PS. et al; PROWESS-SHOCK Study Group. Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med 2012; 366 (22) 2055-2064
    CrossrefPubMedGoogle Scholar
  • 21 Vincent JL, Francois B, Zabolotskikh I. et al; SCARLET Trial Group. Effect of a recombinant human soluble thrombomodulin on mortality in patients with sepsis-associated coagulopathy: the SCARLET randomized clinical trial. JAMA 2019; 321 (20) 1993-2002
    CrossrefPubMedGoogle Scholar
  • 22 Wada H, Honda G, Kawano N. et al. Severe antithrombin deficiency may be associated with a high risk of pathological progression of DIC with suppressed fibrinolysis. Clin Appl Thromb Hemost 2020; 26: 1076029620941112
    CrossrefPubMedGoogle Scholar
  • 23 Kawasugi K, Wada H, Honda G. et al. Hypofibrinogenemia is associated with a high degree of risk in infectious diseases: a post-hoc analysis of post-marketing surveillance of patients with disseminated intravascular coagulation treated with thrombomodulin alfa. Thromb J 2021; 19 (01) 12
    CrossrefPubMedGoogle Scholar
  • 24 Singer M, Deutschman CS, Seymour CW. et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 2016; 315 (08) 801-810
    Google Scholar
  • 25 Bernard GR, Vincent JL, Laterre PF. et al; Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344 (10) 699-709
    CrossrefPubMedGoogle Scholar
  • 26 Kienast J, Juers M, Wiedermann CJ. et al; KyberSept investigators. Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. J Thromb Haemost 2006; 4 (01) 90-97
    CrossrefPubMedGoogle Scholar
  • 27 Levi M, Vincent JL, Tanaka K. et al. Effect of a recombinant human soluble thrombomodulin on baseline coagulation biomarker levels and mortality outcome in patients with sepsis-associated coagulopathy. Crit Care Med 2020; 48 (08) 1140-1147
    CrossrefPubMedGoogle Scholar
  • 28 Takemitsu T, Wada H, Hatada T. et al. Prospective evaluation of three different diagnostic criteria for disseminated intravascular coagulation. Thromb Haemost 2011; 105 (01) 40-44
    Article in Thieme ConnectPubMedGoogle Scholar
  • 29 Iba T, Umemura Y, Wada H, Levy JH. Roles of coagulation abnormalities and microthrombosis in sepsis: pathophysiology, diagnosis, and treatment. Arch Med Res 2021; 52 (08) 788-797
    CrossrefPubMedGoogle Scholar
  • 30 Yasuda N, Goto K, Ohchi Y, Abe T, Koga H, Kitano T. The efficacy and safety of antithrombin and recombinant human thrombomodulin combination therapy in patients with severe sepsis and disseminated intravascular coagulation. J Crit Care 2016; 36: 29-34
    CrossrefPubMedGoogle Scholar